Specifically, the kits provide prior authorization information for PCSK9 inhibitors to treat lipid disorders, direct oral anticoagulants for stroke prevention and angiotensin receptor-neprilysin inhibitors for heart failure treatment. Those three categories of drugs were commonly pinpointed as being “always” or “often” denied by insurance companies in surveys of providers.